Search

Your search keyword '"Ajayi, Temitayo"' showing total 185 results

Search Constraints

Start Over You searched for: Author "Ajayi, Temitayo" Remove constraint Author: "Ajayi, Temitayo"
185 results on '"Ajayi, Temitayo"'

Search Results

1. Combination Chemotherapy Optimization with Discrete Dosing

2. On strong duality, theorems of the alternative, and projections in conic optimization

4. A Gilmore-Gomory-Type Construction of Integer Programming Value Functions

6. Theorems of the Alternative for Conic Integer Programming

7. Approximate Submodularity and Its Implications in Discrete Optimization

13. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

16. Combination Chemotherapy Optimization with Discrete Dosing.

18. Pegcetacoplan compared with supportive care for 26 weeks for participants with paroxysmal nocturnal hemoglobinuria: a plain language summary

23. Plain language summary of PEGASUS, a study comparing pegcetacoplan with eculizumab for 16 weeks in people with paroxysmal nocturnal hemoglobinuria

25. Microbial content and elemental analysis of some locally prepared herbal remedies (Agbo) in Ibadan metropolis.

26. Poster: MDS-112 Normalization of Hematologic and Health-Related Quality of Life Markers in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Pegcetacoplan and Baseline Hemoglobin at or Above 10 g/dL

32. Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

33. Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter

38. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

41. The Gap Function: Evaluating Integer Programming Models over Multiple Right-Hand Sides.

42. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration

43. Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS)

49. Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis

50. Neurofilament light is a treatment‐responsive biomarker in CLN2 disease

Catalog

Books, media, physical & digital resources